NovoCure (NVCR) EBT Margin (2014 - 2026)

NovoCure has disclosed EBT Margin across 13 years of filings, most recently posting 39.79% for Q1 2026.

• EBT Margin for Q1 2026 came in at 39.79%, down 2024.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 25.98% (down 510.0% YoY), and the FY2025 annual result was 20.79%, up 88.0% from the prior year.
• EBT Margin came in at 39.79% for Q1 2026 at NovoCure, down from 23.49% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 1.83% in Q1 2022 to a low of 42.76% in Q2 2023.
• The 5-year median for EBT Margin is 22.85% (2024), against an average of 24.81%.
• Across the five-year window, EBT Margin sank 3998 bps in 2023 and jumped 2765 bps in 2024, its largest moves.
• NovoCure's EBT Margin stood at 25.35% in 2022, then fell by 14 bps to 28.8% in 2023, then declined by 19 bps to 34.23% in 2024, then jumped by 31 bps to 23.49% in 2025, then plunged by 69 bps to 39.79% in 2026.
• The last three EBT Margin figures came in at 39.79% (Q1 2026), 23.49% (Q4 2025), and 17.96% (Q3 2025), per Business Quant data.